Compared to TNF-alpha inhibitors, exposure to IL-23 inhibitors was associated with a significantly lower risk of paradoxical eczema, whereas no significant difference in incidence was observed between TNF-alpha inhibitors and IL-17 inhibitors [11]. The gene discussed is IL23A; the disease is Eczematoid dermatitis.